Anna Grenabo Bergdahl
Papers
4
Total Citations
59
H-Index
3
About
Anna Grenabo Bergdahl is a urological oncologist and clinical researcher specializing in the surgical management of testicular cancer, with a particular focus on retroperitoneal lymph node dissection (RPLND) as a treatment strategy for germ cell tumors. Her work sits at the intersection of surgical innovation and oncological outcomes, addressing a critical clinical challenge: reducing the long-term toxicity burden associated with conventional chemotherapy and radiotherapy for metastatic seminoma. As a leading contributor to the Swedish Norwegian Testicular Cancer Group (SWENOTECA), Bergdahl has helped shape population-based evidence for primary RPLND in low-volume metastatic seminoma, demonstrating its oncological efficacy and surgical safety as a compelling alternative to cytotoxic therapies. Her 2022 study on robotic RPLND, garnering 30 citations, established robot-assisted surgery as a viable option at national referral centres, while her 2024 population-based cohort study (19 citations) further strengthened the evidence base for surgical-first approaches. Through prospective trials and international collaborations with centres such as Cologne, Bergdahl is actively redefining treatment paradigms for testicular cancer, offering patients pathways to cure that meaningfully preserve long-term quality of life.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4